Venue: Virtual
Date: 07/09/2021
Time: 15:00 - 18:00
The discovery and development of T-cell redirecting modalities, such as bispecific antibodies and CAR-Ts, holds great promise for patients with multiple myeloma and other hematological malignancies, such as lymphoma and acute myeloid leukemia.
Johnson & Johnson Innovation, in collaboration with Janssen Research & Development, LLC’s Oncology Therapeutic Area, will host a virtual scientific and strategic partnering event on state-of-the-art developments in immune cell engagers in hematological malignancies, bringing together entrepreneurs, start-ups, researchers, and scientists from across Europe and beyond. They also want to explore how Johnson & Johnson Innovation could collaborate with the aim to support opportunities and enable innovators and their innovations to reach full therapeutic potential for patients.
DANISH BIO – DANSK BIOTEK members are most welcome to join on September 7. Registration and information on speakers can be found here.